Randomized trial evaluates CSF chi3l2 for predicting faster disability progression in ALS, indicating its potential as a biomarker.
To evaluate the diagnostic and prognostic value of cerebrospinal fluid (CSF) chitinase-3-like protein 2 (CHI3L2) in amyotrophic lateral sclerosis (ALS).
No takes yet. Share an insight, caveat, or question.
Xie et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: